PKF supports acquisition and re-admission to the Main Market of the London Stock Exchange
We are delighted to have supported Solvonis Therapeutics plc on their re-admission to the Main Market of the London Stock Exchange, and the acquisition of Awakn Life Sciences Corp.
Solvonis Therapeutics plc has raised gross proceeds of £2 million, through the issue of 1,538,461,529 new ordinary shares of 0.1 pence each in the Company, with certain existing and new institutional and other investors at the Issue Price of 0.13 pence per Fundraise Share.
Solvonis Therapeutics plc is a clinical-stage biotechnology company, co-developing therapeutics for mental health and substance abuse disorders.
“We were grateful for the support and expertise of the Transaction Services team at PKF. We have enjoyed working with them on a number of transactions, and look forward to working with them again in the future.”
Anthony Tennyson, CEO, Solvonis Therapeutics plc
PKF acted as reporting accountant on the transaction and the Capital Markets team included Adam Humphreys, Sam Bradshaw and Kiran Gukhool.
Find out more about how our Capital Markets team can support you and your business here.
